Skip to Content

Omeros Corp OMER

Morningstar Rating
$2.46 −0.08 (2.96%)
View Full Chart
Unlock Our Analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

OMER is trading within a range we consider fairly valued.
Price
$2.53
Fair Value
$4.78
Uncertainty
Extreme
1-Star Price
$94.65
5-Star Price
$9.29
Economic Moat
Xfg
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if OMER is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$2.54
Day Range
$2.292.50
52-Week Range
$0.937.77
Bid/Ask
$2.44 / $2.45
Market Cap
$154.65 Mil
Volume/Avg
121,279 / 737,240

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield
Dividend Yield (Forward)
Total Yield

Company Profile

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
196

Valuation

Metric
OMER
Price/Earnings (Normalized)
Price/Book Value
Price/Sales
Price/Cash Flow
Price/Earnings
OMER

Financial Strength

Metric
OMER
Quick Ratio
2.35
Current Ratio
2.39
Interest Coverage
−5.20
Quick Ratio
OMER

Profitability

Metric
OMER
Return on Assets (Normalized)
−32.23%
Return on Equity (Normalized)
−840.03%
Return on Invested Capital (Normalized)
−42.19%
Return on Assets
OMER

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRLzsr$454.3 Bil
VRTX
Vertex Pharmaceuticals IncGqlphj$90.4 Bil
REGN
Regeneron Pharmaceuticals IncJpqkhjc$89.7 Bil
SGEN
Seagen Inc Ordinary SharesJkcmtqp$40.2 Bil
MRNA
Moderna IncWlx$30.5 Bil
ARGX
argenx SE ADRRxrg$27.3 Bil
BNTX
BioNTech SE ADRNsl$23.8 Bil
ALNY
Alnylam Pharmaceuticals IncBwsgwqk$21.7 Bil
BMRN
Biomarin Pharmaceutical IncWnpfrl$17.8 Bil
INCY
Incyte CorpCrbvmk$12.3 Bil